United States Atopic Dermatitis (AD) Epidemiology Forecast to 2030 – ResearchAndMarkets.com – Business Wire

DUBLIN–()–The “Atopic Dermatitis (AD) – US Epidemiology Forecast to 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This ‘Atopic Dermatitis (AD) – Epidemiology Forecast-2030’ report delivers an in-depth understanding of the disease, historical and forecasted Atopic Dermatitis (AD) epidemiology in the United States.

Atopic Dermatitis (AD) Epidemiology Perspective

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Population of Atopic Dermatitis, Diagnosed Prevalent Population of Atopic Dermatitis, Severity-specific Distribution of Atopic Dermatitis in Adults, Severity-specific Distribution of Atopic Dermatitis in Pediatric Population and Gender-specific Distribution of Atopic Dermatitis in Adults in the United States market from 2018 to 2030.

Atopic Dermatitis (AD) Detailed Epidemiology Segmentation

  • The total prevalent population of AD in the United States was estimated to be 32,197,083 in 2020.
  • The total diagnosed prevalent population of AD in the United States was estimated to be 25,091,967 in 2020.
  • The prevalent population of AD in the United States is expected to increase at a CAGR of 0.58% during the study period 2018-2030.
  • In the United States, the total number of adult cases of AD comprised of 5,684,566 males and 9,421,907 females in 2020.
  • The total number of cases of mild AD were 9,065,394 in the United States, in 2020, as compared to the cases of moderate and severe AD with 4,365,771 and 1,661,712 cases respectively, in adults.
  • In children, the total number of cases of mild AD were 6,690,281, in 2020, as compared to the cases of moderate and severe AD with 2,596,228 and 698,985 cases respectively, in the United States.

Scope of the Report

  • The report covers the descriptive overview of Atopic Dermatitis (AD), explaining its causes, signs and symptoms, pathophysiology.
  • The report provides insight into the historical and forecasted patient pool covering the United States.
  • The report assesses the disease risk and burden and highlights the unmet needs of Atopic Dermatitis (AD).
  • The report provides the segmentation of the disease epidemiology for the United States by Prevalent Population of Atopic Dermatitis, Diagnosed Prevalent Population of Atopic Dermatitis, Severity-specific Distribution of Atopic Dermatitis in Adults, Severity-specific Distribution of Atopic Dermatitis in Pediatric Population and Gender-specific Distribution of Atopic Dermatitis in Adults.

Report Highlights

  • Ten Year Forecast of Atopic Dermatitis (AD)
  • The United States Coverage
  • Total prevalent population of Atopic Dermatitis (AD).
  • Total diagnosed prevalent population of Atopic Dermatitis (AD).
  • The publisher has analysed gender-specific distribution of AD. As per the analysis, AD is more prevalent in females than in males.
  • In addition, severity-specific data of AD was analyzed, according to which the adult and pediatric population of AD can be categorized as mild, moderate and severe AD. As per The estimates, it has been found that the mild form of AD included maximum cases, while minimum number of cases were found in severe form of AD in both the populations. This trend is clearly evident in the United States for the study period 2018-2030.

Analyst Comments

  • Various epidemiology studies and international surveys on the prevalence of AD have been conducted in the US. Data from these studies indicate that AD is a common skin disease in both children and adults, predominantly in the adult female population. Some studies have also indicated a three-fold increase in the past few decades.

Key Questions Answered

  • What is the disease risk, burden and unmet needs of Atopic Dermatitis (AD)?
  • What is the historical Atopic Dermatitis (AD) patient pool in the United States?
  • What would be the forecasted patient pool of Atopic Dermatitis (AD) at the United States level?
  • What will be the growth opportunities in the United States with respect to the patient population pertaining to Atopic Dermatitis (AD)?
  • At what CAGR the population is expected to grow in the United States during the forecast period (2021-2030)?

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Key Topics Covered:

1 Key Insights

2 Report Introduction

3 Executive Summary

4 SWOT Analysis

5 Disease Background and Overview

5.1 Signs and Symptoms

5.2 Causes and Triggers

5.3 Clinical presentation

5.4 Pathophysiology

5.5 Skin hypersensitivity – abnormalities of the horny cell layer

5.5.1 Mechanisms involved in inflammation

5.5.2 Pruritus

5.6 Biomarkers

5.6.1 Serum IgE levels

5.6.2 Peripheral eosinophil count

5.6.3 Serum lactate dehydrogenase level

5.6.4 Serum thymus and activation regulated chemokine level

5.7 Characteristics of eruption

5.7.1 Infancy (younger than 2 years)

5.7.2 Childhood/school-age (2-12 years old)

5.7.3 Adolescence/adulthood (13 years and older)

5.8 Differential diagnosis

5.9 Prevention and Management

5.10 Diagnosis

5.11 Diagnostic criteria for eczema

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 United States

6.2.1 Assumption and Rationale

6.2.2 Prevalent Population of Atopic Dermatitis in the United States

6.2.3 Diagnosed Prevalent Population of Atopic Dermatitis in the United States

6.2.4 Severity-specific distribution of Atopic Dermatitis in Adults in the United States

6.2.5 Severity-specific distribution of Atopic Dermatitis in Pediatric Population in the United States

6.2.6 Gender-specific Prevalence of Atopic Dermatitis in Adults in the United States

7 Recognized Establishments

8 Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/dvj315